SEW2871 is a potent sphingosine-1-phosphate receptor type-1 (S1P 1 )-selective agonist that induces peripheral lymphopenia through sequestration of lymphocytes into secondary lymphoid organs, similar to the non-selective sphingosine-1-phosphate (S1P) receptor agonist FTY720. FTY720 has been reported to interfere with human dendritic cell (DC) effector functions and both FTY720 and SEW2871 have been shown to modulate murine DC trafficking in vivo. Little is known about the possible effects of SEW2871 on human and murine DC functions. Here, we demonstrate that in contrast to FTY720, SEW2871 does not induce down-regulation of S1P 1 in human DCs and thus does not exert a functional antagonism at S1P 1 . Notably, the compound was found to impair chemotaxis of immature and mature human DCs in vitro, possibly by interfering with the activation of p44/p42 and p38 mitogen-activated protein kinase signaling pathways. Comparative FACS analyses show that SEW2871 mediates CD18 down-regulation on mature human DCs. The influence on DC migration could be confirmed with in vivo assays using BALB/c mice in which SEW2871 impairs the migration of CD11c1 DC and CD2071 Langerhans cells (LC) to the draining lymph nodes (LNs) under inflammatory conditions. These results suggest that the S1P-S1P 1 axis might not only control lymphocyte trafficking but also play a pivotal role in DC migration from the skin to LN.
Introduction
The sphingosine-1-phosphate (S1P)-sphingosine-1-phosphate receptor type-1 (S1P 1 ) axis controls lymphocyte trafficking and distribution within lymphoid organ compartments. By the availability of synthetic high-affinity S1P receptor agonists-that elicit lymphocyte sequestration inside lymphoid organs-this immunoregulatory system became a promising target for immunosuppressive therapy. S1P 1 is expressed in endothelial cells and in a variety of immune cells including T cells, B cells, macrophages and dendritic cells (DCs). Signaling via S1P 1 has pleiotropic effects on different types of immune cells and endothelial cells, and thus it still remains challenging to precisely determine the cellular basis of S1P 1 -mediated immunosuppression (1) .
DCs-as the most important antigen-presenting cells in the immune system-hold a key position in the induction of adaptive immune responses and immune tolerance (2) . Several studies have elucidated a clear role for the S1P-S1P receptor system in human and mouse DC: murine skinderived immature Langerhans cells (LC) (3), a subpopulation of epithelial tissue-specific DCs recruited to the epidermis, as well as murine in vivo DC (4) and human DCs that are derived by in vitro differentiation of human leucocytes in the presence of IL-4 and granulocyte macrophage colonystimulating factor (GM-CSF) express mainly S1P 1 , S1P 2 , S1P 3 and S1P 4 , which are coupled to the regulation of cytokine production and migration of these cells (5) . We have previously shown that the non-selective S1P receptor agonist FTY720 interferes with human DC migration, cytokine production and T cell stimulatory function in vitro. Recent observations have reported a pivotal role for S1P 1 -dependent signaling in the regulation of DC migration: DCs, including immature LC, depend on proper S1P signaling for migration and pre-treatment with the non-selective S1P receptor agonist FTY720 efficiently inhibits DC migration in vitro and in vivo (6) .
SEW2871 is a novel selective full agonist of human and murine S1P 1 structurally unrelated to S1P that induces and maintains a rapid and dose-dependent peripheral blood lymphopenia in mice via a S1P 1 -mediated mechanism. There is histological evidence that SEW2871 similar to FTY720 inhibits transendothelial lymphocyte migration into murine lymphatic sinuses by induction of log-jamming of lymphocytes immediately subjacent to sinus-lining endothelium (7) (8) (9) .
In animal models of renal transplantation, FTY720 and SEW2871 have been shown to ameliorate renal ischemia/ reperfusion injury by inhibiting lymphocyte egress and reducing pro-inflammatory molecules (10) . S1P and SEW2871-upon S1P signaling through the endothelial S1P 1 receptor-have been identified to exert a potent antiinflammatory action by preventing monocyte adhesion to aorta in tumor necrosis factor (TNF)-a-treated mice in vivo (11) . Despite many similarities of FTY720 and SEW2871, the molecular mode of action is not identical. FTY720-phosphate (FTY720-P)-the active metabolite of FTY720-is known to induce internalization and degradation of S1P 1 , resulting in receptor down-regulation. In contrast, SEW2871 induces S1P 1 internalization and recycling, mimicking the action of the natural ligand S1P, and thus functional antagonism was suggested not to be essential for induction of reversible lymphopenia (12) . At a molecular level, SEW2871 modulates multiple signals triggered by S1P 1 comparably to S1P, including GTPcS binding, calcium flux, Akt and extracellular signal-regulated kinase (ERK)1/2 phosphorylation. Therefore, temporary phosphorylation of ERK and Akt was concluded to be sufficient to activate effector pathways that maintain lymphopenia.
Little is known about the exact mechanisms of S1P 1 -mediated regulation of human and mouse DC trafficking. In the present study, we have investigated the influence of SEW2871 on human monocyte-derived dendritic cells (moDCs), human CD1c
+ peripheral blood dendritic cells (bloodDCs) and on CD11c + DC and CD207 + LC in mice.
Methods

Reagents
SEW2871 was purchased from Calbiochem, La Jolla, CA, USA, and diluted in Dimethyl sulfoxide (DMSO) (SigmaAldrich, St Louis, MO, USA).
Animals
Mice of the inbred strain BALB/c were purchased from Charles River Germany, Sulzfeld, Germany, and used at 2-5 months of age. Animals were anesthetized with intraperitoneal (i.p.) injections of Vetanarcol (Intervet, Vienna, Austria). All experiments were conducted according to the National and EU Institutional Guidelines.
Generation of mo-DCs
Human mo-DCs were prepared according to a protocol described by Romani et al. (13 ; Novartis, Basel, Switzerland) and 1000 U ml À1 IL-4 (Strathmann Biotech, Hamburg, Germany) on the first and second day and 1600 U ml À1 GM-CSF and 1000 U ml À1 IL-4 on the following 6 days. On day 6, maturation cocktail consisting of 10 ng ml À1 IL-1b (PreproTech, London, UK), 10 3 U ml À1 IL-6 (Strathmann Biotech), 10 ng ml
À1
TNF-a (specific activity 6 3 10 7 U mg
; gift of G. R. Adolf Bender, Vienna, Austria) and 1 lg ml À1 prostaglandin E 2 (Pharmacia and Upjohn, Puurs, Belgium) was added to induce maturation in some immature DCs (iDCs). On day 8, generated iDCs were CD83 À , CD86 low and mature DCs (mDCs) were CD83
+ and CD86 high as analyzed by flow cytometry.
Isolation of human CD1c
+ blood DCs
In brief, CD1c + blood DCs were obtained from healthy blood samples after Ficoll gradient centrifugation, E-rosetting and a two immunomagnetic sorting step using DC Isolation Kit (MACS TM ; Miltenyi Biotec) according to the manufacturer's guidance. The resulting highly purified blood-DCs were ;95% CD1c + , CD19 neg .
Analysis of DC apoptosis
DC apoptosis was monitored by staining of phosphaditylserine translocation with Annexin V in combination with propidium iodide (PI) using the Annexin V-FITC Apoptosis Detection Kit (Alexis Biochemicals, Lausen, Switzerland) according to the manufacturer's instructions. N-Acetyl-D-sphingosine (50 lM; C2-ceramide, Sigma-Aldrich, Vienna, Austria) and DMSO (10 lM) treated DCs were used as control populations.
Antibodies for phenotypical studies of DC by flow cytometry FITC-and PE-conjugated mAbs against following molecules were used: CD40-FITC, CD80-FITC, CD86-FITC, CD83-FITC, HLA ABC-FITC, HLA DR-FITC, CD1a-FITC, CD11a-FITC, CD11b-PE, CD18-FITC, CD31-FITC, CD54-PE, CD50-FITC, CD58-FITC (all BD Pharmingen San Diego, CA, USA) and CD11c-FITC (DakoCytomation, Glostrup, Denmark). Specimens were analyzed on a FACSCalibur instrument using CellQuest software (BD Biosciences, San Jose, CA, USA).
Induction of skin DC migration into skin-draining lymph nodes
For the in vivo skin DC migration experiments, mice were evaluated in three groups. Mice were pre-treated with 20 lg (0.5 mg kg À1 ) of SEW2871 into the left pinna and vehicle (5% DMSO in PBS) into the right pinna. After 60 min, dorsal ear sides were topically treated with either 20 ll of 1% of the contact allergen 2,4,6-trinitro-1-chlorobenzene (TNCB, picryl chloride; Kodak Eastman, Rochester, NY, USA) or 20 ll vehicle (acetone:olive oil, 4:1). Twelve hours later, SEW2871 (0.5 mg kg
À1
) and vehicle were applied again. One control group received only 20 ll of 1% TNCB on the left ear. Skindraining lymph nodes (LNs) were excised 36 h later.
Isolation of LN DCs and FACS analysis
Skin-draining LNs (auricular) were excised 36 h after application of the contact allergen. Cell suspensions of auricular LNs were prepared by incubation at 37°C for 25 min in Hank's containing DNAse I and collagenase P (both Roche, Mannheim, Germany). EDTA 5 mM was added for additional 5 min. Digested LNs were pressed through cell strainers (Falcon Labware, Oxnard, CA, USA) and washed twice in PBS supplemented with 5 mM EDTA.
For intracellular staining of Langerin/CD207, the Cytofix/ Cytoperm TM kit (BD Pharmingen) was used according to the manufacturer's guidance. Permeabilized LN cells were labeled with anti-CD11c-PE (clone HL3, BD Pharmingen) and anti-Langerin/CD207-Alexa488 
F-actin polymerization analysis
iDCs and mDCs (1 3 10 6 ) were added to 96-well cell culture cluster v-bottom plates (Costar, Bethesda, MD, USA) and stimulated with CCL5 (20 ng ml À1 ), CXCL12 (1 lg ml À1 ) or CCL19 (20 nM; all PreproTech). After 25, 60 and 120 s in iDCs and 25, 90 and 180 s in mDCs, f-actin polymerization was stopped using 2% formaldehyde (SAV Liquid Production, Flintsbach, Bayern, Germany). Cells were perforated and stained in a medium containing 10% L-alpha-lysophosphatidylcholine (Sigma-Aldrich), 20% N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl)-phallacidin (Molecular Probes, Eugene, OR, USA), 2% formaldehyde and PBS (PAA Laboratories) for 20 min. After washing with FACS buffer, quantification of f-actin was measured by FACS analysis.
Chemotaxis assay
The apparatus consists of two 48-well microchemotaxis chambers (Neuroprobe, Bethesda, MD, USA) separated by an 8-lm pore nitrocellulose filter (Sartorius, Gö ttingen, Germany). iDCs or mDCs (1 3 10 6 cells per ml) were placed in the upper chamber (50 ll per well), chemokines [iDC: CCL5 (20 ng ml À1 ), CXCL12 (1 lg ml À1 ); mDC: CCL19 (10 nM), CCL21 (1 lg ml À1 ), (PreproTech)] or RPMI 1640/0.5% BSA (control medium) were added in the bottom chamber (30 ll per well). After an incubation time of 4 h, migration depth of cells into the filter was quantified by microscopy, measuring the distance from the surface of the filter to the leading front of cells. Data are expressed as the chemotaxis index: the distance of cells that migrated in response to chemokines relative to the distance of cells that migrated randomly into the nitrocellulose filters.
Western blotting
Cells were harvested and lysates were obtained by resuspending the pellets in European Organization for Research and Treatment of Cancer buffer [20 nM NaH 2 PO 4 (pH 7.5), 1 mM EDTA and 10% glycerol], phenylmethylsulfonyl fluoride, sodium fluoride and a cocktail of protease inhibitors (Protease Inhibitor Cocktail Set III; Calbiochem-Novabiochem, San Diego, CA, USA) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail 2, Sigma-Aldrich). Insoluble portion was removed by centrifugation and protein content was determined by using the Bradford method. Equal amounts of proteins were resolved into 4-12% Bis-Tris gel (Invitrogen, Leek, The Netherlands) and transferred onto a nitrocellulose membrane (Invitrogen). Membranes were blocked for 1 h at room temperature using Starting Block buffer (Pierce Biotechnology, Rockford, IL, USA) and incubated at 4°C overnight in the same buffer after addition of Tween-20 (0.05%) and primary antibodies. Afterward, membranes were washed with Tris-buffered saline buffer and incubated for 1 h at room temperature with fluorescence-labeled secondary antibodies (Molecular Probes). Detection and quantifications of bands were performed by using Odyssey Infrared Imaging System (LiCor Biosciences, Lincoln, NE, USA).
Antibodies used for western blots
Mouse anti-human (S1P 2 , S1P 3 and S1P 4 ) and rabbit anti-human (S1P 1 ) antibodies (Exalpha Biologicals, Watertown, MA, USA), mouse anti-actin antibody (Chemicon, Hampshire, UK), rabbit anti p44 and p42 antibodies, mouse anti RhoA antibody and goat anti Akt1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti p38-MAPKinase antibody, rabbit anti cofilin antibody, mouse anti phospho p44 and p42 antibodies, rabbit anti phospho p38-MAPKinase antibody, rabbit anti phospho Akt1 antibody and rabbit anti phospho cofilin antibody (Cell Signaling Technology, Danvers, MA, USA).
Statistical analysis
Data are expressed as means 6 SEMs. Each data set was analyzed for Gaussian distribution using KolmogorovSmirnov test. Statistical evaluation was performed using Kruskal-Wallis test and Mann-Whitney U-test (Figs 1-9 ). In case of multiple comparisons, Bonferroni correction was applied. Statistical analysis of data shown in Fig. 7 were assessed by using Welch's corrected unpaired two-sided Student's t-test.
Results
S1P receptor protein expression in mo-DCs is not affected by SEW2871
One current theory, referred to as 'functional antagonism', states that some S1P receptor agonists such as FTY720-P internalize and degrade S1P 1 on lymphocytes, resulting in receptor down-regulation. Of note, we have previously shown that human DCs express a distinct S1P receptor profile and that treatment of human mo-DCs (mo-DCs) with FTY720 and FTY720-P results in down-regulation of S1P 1 and S1P 4 . Therefore, it was of interest to whether SEW2871 affects the expression of S1P [1] [2] [3] [4] in mo-DCs. Protein expression of S1P [1] [2] [3] [4] was compared between mo-DCs that were generated in the presence of defined SEW2871 concentrations (0.01-10 lM) and untreated control cells by the use of mAbs. Immature (CD83 À and CD86 low+ ) and mature (CD83 + and CD86 high ) mo-DCs were collected on day 8 of culture. The results of western blot analysis are shown in Fig. 1 . Both immature mo-DCs and mature mo-DCs express S1P 1 , S1P 2 , S1P 3 and S1P 4 . Interestingly, S1P 1 levels varied between untreated and SEW2871-treated immature mo-DCs at high drug concentrations (10 lM). S1P 2 levels in immature mo-DCs and S1P 3 levels in mature mo-DCs appeared slightly affected by increasing drug concentrations; however, the differences between treated and untreated cells did not reach statistical significance.
Chemotaxis of in vitro generated iDCs and mDCs is impaired by SEW2871
Recently, we have shown that human iDCs and mDCs exhibit impaired capability to migrate toward DCs attracting chemokines after exposure to FTY720/FTY720-P. To examine whether SEW2871 affects human mo-DC chemotaxis, in vitro-generated immature mo-DCs on day 7 and mature mo-DCs on day 8 of culture were pre-treated with SEW2871 for 5 h and subjected to chemotaxis assays using defined DC chemokines (immature mo-DC: CCL5 and CXCL12; mature mo-DC: CCL19, CCL21).
As shown in Fig. 2 , pre-treatment with increasing drug concentrations (0.01-1 lM) resulted in a dose-dependent reduction of migration in response to all investigated chemokines in immature and mature mo-DCs. To address whether this effect can also be observed with blood-DCs, CD11c + DCs were isolated from human blood samples of healthy volunteers in an immature phenotype (CD86 low+ , CD83 À ; data not shown) and matured for 48 h in vitro with the defined cytokine mix. Again, cells were exposed to different concentrations of SEW2871 (0.01-1 lM) 5 h prior to subjecting cells to migration experiments. Comparable effects to those evoked in mo-DCs were observed in immature and mature bloodDCs (Fig. 2) .
SEW2871 does not affect f-actin polymerization or cofilin phosphorylation
Riol-Blanco et al. (14) reported that the Rho/cofilin/f-actin pathway plays a pivotal role in regulating the migratory speed of DCs without directly influencing DC chemotaxis. FTY720 have been shown to interfere with the polymerization of globular-actin (g-actin) to filamentous actin (f-actin) in human DCs.
Thus, we tested whether SEW2871 interferes with migratory speed by modulating the Rho-cofilin/actin pathway. Filamentous actin was measured by FITC-phalloidin staining and FACS analysis of chemokine-stimulated mo-DCs (immature mo-DC: CCL5, CXCL12; mature mo-DC: CCL19). After 25, 60 and 120 s in immature and 25, 90 and 180 s in mature mo-DCs, f-actin polymerization was stopped with 2% formaldehyde. Fig. 1 . Western blot analysis of S1P receptor expression in SEW2871-treated immature and mature mo-DCs. Fifty micrograms of protein lysate from iDC and mDC mo-DCs treated with the indicated concentrations of SEW2871 (SEW2871-DC) and untreated control mo-DC (Co-DC) were analyzed for protein expression of S1P 1 , S1P 2 , S1P 3 and S1P 4 on a western blot. No significant differences in the relative S1P receptor expression could be detected between SEW2871-DC and untreated Co-DC. Bars represent expression levels relative to untreated control (n = 4).
Because cofilin can regulate cell motility through its ability to depolymerize and sever actin filaments at the leading edges, we studied the influence of SEW2871 on Ser-3 cofilin phosphorylation. Stimulation of immature mo-DCs with CCL5 and CXCL12 for 4 min caused marked cofilin phosphorylation.
No effects on f-actin polymerization or Ser-3 cofilin phosphorylation were observed in SEW2871-treated DCs (Figs 3  and 4) . These results indicate that SEW2871 does not affect migratory speed of human mo-DCs.
SEW2871 modulates MAPK signaling upon chemokine receptor activation
Activation of different members of the MAPK family (p44/p42 and p38 MAPK) is of critical importance in the downstream signaling pathways after chemokine receptor stimulation. Thus, we analyzed the molecular signaling events upon S1P 1 receptor agonism by SEW2871 at a baseline level-i.e. without simultaneous chemokine stimulation-and in the setting of simultaneous stimulation with defined DC chemokines.
SEW2871-treated (0.01-10 lM) and untreated immature and mature mo-DCs (control DCs), cultured for 8 days, were lysed and the lysates were analyzed by western blots using antibodies specific for the phosphorylated (phospho) and unphosphorylated forms of p44, p42 and p38 MAPK. Significantly lower expression levels of phospho-p44 in immature and phospho-p42 in mature SEW2871-treated mo-DCs were detected. No effect on p38 MAPK expression became evident ( Fig. 5 and supplementary figure 1 , available at International Immunology Online). After having observed distinct effects in unstimulated mo-DCs, the same experiments were repeated with chemokine stimulated DCs (immature mo-DC: CCL5, CXCL12, mature mo-DC: CCL19). After 4 min, cells were fixed with 2% formaldehyde. In this setting, higher expression levels of phospho-p44, phospho-p42 and phospho-p38 MAPK were detectable. Immature SEW2871-mo-DCs were found to express lower levels of phosphop44, phospho-p42 and phospho-p38 MAPK, whereas in mature mo-DCs, lower expression levels of p44 and p42 were detected (Fig. 6 and supplementary figure 2 , available at International Immunology Online).
These data indicate that upon agonist activation of S1P 1 by SEW2871, specific post-receptor signaling events resulting in inappropriate MAPK activation might + DC were pre-treated with the indicated concentrations of SEW2871 for 5 h. Starting at low micromolar concentrations, SEW2871 dose dependently inhibited iDCs and mDC chemotaxis toward DCs attracting chemokines (mDC: CCL19, CCL21; iDC: CXCL12, CCL5). Data are represented as means of the chemotaxis index (ratio between migration distance of cells toward chemokines and control medium). n = 3,*P < 0.05, **P < 0.01, ***P < 0.001.
hamper the chemotactic responses of DC toward DC chemokines.
SEW2871 impairs contact allergen induced-migration of mouse LCs and total CD11c
+ skin DC numbers to the skin-draining LNs
To further outline the influence of SEW2871 on DC migration, we expanded our experiments to an in vivo approach in BALB/c mice. In a contact dermatitis model (15), we topically applied the contact allergen TNCB on ear skin to induce a strong inflammation in the treated area, which leads to migration of skin DCs to the draining auricular LNs. SEW2871 or vehicle (DMSO 5%) was simultaneously injected intra-dermally into the ears. In accordance with the emigration of skin DCs from the TNCB-inflamed skin, the draining LNs were swollen. When LN cell suspensions were analyzed after 36 h, we observed that cellularity, i.e. total cell numbers, increased 2-to 3-fold when compared with untreated mice. With the mAb detecting Langerin (CD207 + ), we compared LC densities with the LN cell supensions of SEW2871-treated mice and vehicle (DMSO 5%)-treated mice. Interestingly, SEW2871 treatment significantly impaired TNCB-induced migration of CD207 + LC and of total CD11c + DC numbers compared with vehicle-treated mice. Our findings clearly demonstrate that SEW2871 reduces the immigration of skin DCs into peripheral LNs under inflammatory conditions in this contact dermatitis model (Fig. 7) .
SEW2871 down-modulates CD18 expression without affecting DC differentiation
To investigate the influence of SEW2871 on mo-DC differentiation, equal numbers of monocytes were cultured with various concentrations of SEW2871 (0.01-1 lM) for 8 days in the presence of GM-CSF and IL-4. Mo-DC maturation was induced on day 6 using a defined cytokine mixture for 2 days. No significant influence on the cell surface expression of differentiation marker molecules (CD1a, CD11c, CD83), MHC class I (HLA ABC) or II (HLA DR) molecules, co-stimulatory molecules (CD40, CD80, CD86) or adhesion molecules (CD11a, CD11b, CD31, CD50, CD54, CD58) was observed. As previously reported for FTY720, a modest reduction in CD18 expression was seen on mature SEW2871-treated DCs (0.01-1 lM) ( Fig. 8A and B) . To exclude a pro-or anti-apoptotic effect, the viability of mo-DCs generated in the presence of the compound (0.01 -10 lM) was compared with control mo-DCs by flow cytometry via Annexin V/PI staining. As shown in Fig. 9 , no significant effect on the incidence of Annexin V+/PIÀ and Annexin V+/PI+ cells could be observed up to a concentration of 10 lM.
Discussion
Ample evidence indicates that the S1P-S1P 1 receptor system constitutes a novel immunoregulatory system. S1P functions in both paracrine and autocrine manners by eliciting many S1P 1 -dependent responses in immune cells. The paracrine effects of S1P are required for the emigration of thymocytes from the thymus, the trafficking of lymphocytes within secondary lymphoid organs (SLO) and the migration of B cells into splenic follicles (16, 17) . There is an emerging range of synthetic S1P receptor agonists that are able to selectively alter immune responses by blocking lymphocyte emigration from SLO through interference with proper signaling via S1P 1 , thereby leading to peripheral lymphopenia and Fig. 4 . Western blot analysis of intracellular cofilin phosphorylation in immature and mature mo-DCs. Equal amounts of iDCs and mDC mo-DCs, stimulated with or without CCL5 or CXCL12, as well as chemokine-stimulated iDC mo-DCs, previously treated with SEW2871 (1 lM) for 8 days were used for western blot analysis to investigate intracellular cofilin phosphorylation. Chemokine-stimulated mo-DCs showed an increased cofilin phosphorylation compared with those not stimulated with CCL5 or CXCL12. No significant changes could be detected between SEW2871-treated and untreated chemokine stimulated mo-DCs (n = 4). Fig. 5 . Western blot analysis of MAPKs in SEW2871-treated immature and mature mo-DCs. Fifty micrograms of protein lysate of iDCs and mDC mo-DCs treated with SEW2871 (0.01-10 lM) and untreated control DCs (Co-DCs) were analyzed for protein expression of the following signaling molecules: p44, p42 and p38-MAPK. SEW2871-treated iDCs were found to express lower levels of p44, whereas SEW2871-treated mDCs showed lower expression levels of p42 (n = 4, *P < 0.05, **P < 0.01). Upper panel: western blot bands. Lower panel: quantification of bands in % of control. compromised immunogenic state. Like lymphocytes, DCs also migrate through the lymph into draining LNs for T cell priming after peripheral antigen capturing. Thus, we intended to further characterize the effects of selective S1P 1 agonism on human and murine DC trafficking by using the novel compound SEW2871. In addition, we investigated a possible SEW2871-dependent modulation of S1P receptors and studied the underlying molecular mechanisms of S1P 1 -mediated signaling involved in DC migration. In chemotaxis assays performed with in vitro generated human mo-DCs, we found that SEW2871 reduces iDC and mDC migration to DC attracting chemokines (Fig. 2) . These findings clearly demonstrate that a selective S1P 1 agonist is able to influence human DC migration as it has been shown for FTY720. Given the fact that FTY720, which binds to all S1P receptors except S1P 2 after its phosphorylation, shows promising clinical efficacy, but also considerable adverse effects (e.g. transient dose-dependent bradycardia) in phase III clinical trials (18) , there is increasing need to fully understand selective receptor contributions to increase efficacy and minimize toxicity.
FTY720 acts as functional antagonist by causing internalization and degradation of S1P 1 on lymphocytes. This theory is also supported by the suppression of S1P-mediated chemotaxis along a gradient of endogenous S1P from the LN to the sinus endothelium by FTY720 (19, 20) .
Our western blot analysis reveals that long time SEW2871 treatment does not cause S1P receptor internalization on human mo-DCs in the absence of cycloheximide (Fig. 1) .
These data go basically along with the findings of Jo et al. who describe short-term internalization and subsequent recycling of S1P 1 to the plasma membrane on HEK293 cells stably transfected with S1P 1 receptors, using cycloheximide to block the synthesis of new S1P 1 . Hence, functional antagonism alone cannot be essential for interfering with DC and lymphocyte migration. Probable mechanisms seem to be reversible structural alterations of the S1P-binding sites that change the affinity of S1P 1 for S1P and reversible uncoupling of S1P 1 from signaling pathways. These mechanisms could provide an explanation for the finding, that SEW2871, as a full agonist on S1P 1 , inhibits S1P-induced DC migration toward DCs attracting chemokines.
Little is known about S1P 1 -mediated transmodulation of different intracellular signal transduction molecules (21) . Members of MAPKs are involved in downstream signaling events following chemokine receptor activation and therefore play a pivotal role to regulate the chemotactic behavior of human DCs (14, 22) . Our findings indicate that SEW2871 impairs basal p44/p42 phosphorylation, as it is shown in migration probably by diminishing the activation of MAPKs after stimulation of different stage-dependent chemokine receptors (Fig. 6) . Because of the lack of information about the proper intracellular mode of action of SEW2871, it is difficult to appreciate whether the cause of this discrepancy lays in the fact of using different cell types or perhaps the long time administration of the compound (8 days).
Another important intracellular signaling molecule for DC migration is cofilin, because cofilin can regulate cell motility through its ability to depolymerize and sever actin filaments at the leading edge.
Recently, Riol-Blanco et al. (14) identified Rho/Pyk2/cofilin as the components of a module that regulates CCR7-dependent migratory speed of human mDCs in a pertussis toxin-insensitive manner. Our data indicate a significant increase of cofilin phosphorylation/inactivation upon chemokine receptor stimulation in iDCs, as it was obtained for mDCs, suggesting the importance of this molecule for DC migration.
SEW2871 does not alter cofilin phosphorylation in iDCs (Fig. 4) . This finding was accompanied by the observation that treatment of iDCs and mDCs with 1 lM SEW2871 did not affect f-actin-polymerization (Fig. 3) .
Interestingly, in a proteomic study aimed at identifying potential mediators of FTY720 in human lymphocytes, eight proteins linked to the cytoskeleton/cell motility were found to be differentially expressed. The expression of cofilin and Epithelial Protein Lost in Neoplasm (EPLIN) was significantly reduced. In contrast, the phosphatase and tensin homologue deleted from chromosome 10 (PTEN), interacting with the phosphoinositide-3 kinase (PI3K)/Akt (protein kinase B) dependent signal transduction and the Ras homologue (Rho) an important regulator of the re-organization of the actin cytoskleteon, showed an increased expression levels (24) .
In our study, the activity of Akt, important for DC survival and migration, was markedly increased in iDCs and mDCs after stimulation of CCR1, 3, 5, CXCR4 and CCR7 by CCL5, CXCL12 and CCL19 for 4 min and SEW2871 did not provoke any changes (data not shown).
Modulation of MAPKs by agents that act through Gprotein-coupled receptors is often mediated by G i proteins (25) . Activation or inactivation of the Rho/cofilin/f-actin or Rho/PTEN pathway (14, 26) is highly associated to G 12/13 proteins in mammalian cells. S1P 1 couples exclusively to G i proteins (27) , we therefore conclude that the action of SEW2871 is strictly limited to certain G i -mediated signaling pathways which is further enforced by our findings that SEW2871 did not alter PTEN activity (data not shown); even more, the transmodulation of only a specific group of all investigated crucially involved chemokine receptor-dependent intracellular signaling molecules favors the hypothesis that SEW2871 might not act via chemokine receptor internalization. Results by Radeke et al. (3) suggest that S1P acts as a potent chemoattractant for immature LC and that S1P 1 and S1P 3 are predominantly involved in the S1P-induced migration. Further studies are required to elucidate the exact SEW2871-mediated intracellular alterations of various receptor signaling pathways and different time intervals, especially long-time administration should be considered.
Given the fundamental importance of skin DC migration into the draining LNs as a prerequisite for the induction of adaptive immune responses, we decided to investigate the influence of SEW2871 on skin DC migration in a contact dermatitis model. For the first time, we show in an in vivo model that SEW2871 treatment of contact-sensitized mice significantly impairs migration of murine LC and CD11c
+ DC into skin-draining LNs under inflammatory conditions (Fig. 7) . Recently, Idzko et al. have clearly demonstrated in a murine asthma model that local application of FTY720 to the lung prior or during antigen challenge inhibits the migration of lung DCs to the draining mediastinal LNs (28) . In accordance with these findings, our results indicate that topical administration of SEW2871 substantially inhibits the + skin DC (A) and CD207 + LC (B) were determined by staining with mAb (anti-CD11c-PE, anti-Langerin/CD207) and flow cytometry. CD11c + cells and CD207 + LC were compared between TNCBstimulated SEW2871-naïve control mice (i.e. DMSO 5%), TNCBstimulated SEW2871-treated (1 mg kg À1 ) mice and unstimulated (TNCB naive) SEW2871-treated (1 mg kg À1 ) mice. A total of six mice were used for each group. Results are shown as mean 6 SD, *P < 0.05. migration of skin DCs to the draining LNs. The here observed effects are not based on an enhanced apoptotic death rate of SEW2871-treated DCs (Fig. 9 ) and can at least be explained by a hampered chemotactic migration rate toward CCR7 (Fig. 2) and a slight reduction in the expression of CD18 (Fig. 8B) . Notably, our in vivo data are underlined to some extent by the findings by Lan et al. (6) who treated B10 mice with i.p. injections of SEW2871 and found increased numbers of blood-DCs after 6 h, which were no longer apparent after 24 h. Interestingly, they could not observe significant changes in LN DC numbers following systemic SEW2871 administration. A possible explanation is provided by the fact that these in vivo results were obtained under steady-state conditions when lower numbers of DCs migrate into LNs via a CCR7-driven dependent chemotactic response.
Taken together, our data increase the understanding concerning the mechanism of action of selective S1P 1 regulation 
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and the different intracellular mechanisms coupled to S1P in DCs. Additionally, this work constitutes a basis for further detailed evaluation of selective S1P 1 receptors as a potential immunomodulatory drug. However, considering transmodulation of multiple receptor-associated pathways will be of critical importance for the development of novel clinically applicable selective S1P 1 modulators.
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